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Endocrine Disruptors and Breast Cancer
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Abstract: Breast cancer strikes one out of eight women in Switzerland. The increase in breast cancer incidence
over the past 70 years parallels an enormous increase of man-made, persistent chemicals in our environment;
some of which have endocrine-disrupting properties in wildlife and/or in animal models. Epidemiological evidence
is strong that a woman’s risk to get breast cancer is linked to her reproductive history and with that to the changes
in her hormonal milieu. Exogenous hormones have also been shown to increase breast cancer risk, however, a
causative link between exposure to endocrine disruptors and human disease is difficult establish as many of these
compounds are ubiquitous and no unexposed controls exist. The synthetic estrogen, diethylstilbestrol (DES), that
was given to pregnant women for three decades, was banned because it was linked to a vaginal carcinoma in
their daughters. It has now been shown that not only women who have taken the drug themselves have increased
breast cancer risk but also their daughters who were exposed in utero. This indicates that breast cancer risk can
be affected by endocrine disruption not only in the adult but already in utero. Evidence from animal models is
accumulating that perinatal exposure to environmentally relevant, low doses of a related compound, bisphenol A
(BPA), alters breast development and increases breast cancer risk. Given the prevalence of endocrine-disrupting
agents they deserve our attention.
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Less than 10% of all breast cancers can
be attributed to genetic factors. Some pa-
tients are born with a bad version of a gene
that predisposes to breast cancer such as
BRCA1, BRCA2, p53, or ATM. Such pa-
tients typically have a strong family history
of breast cancer with various family mem-
bers affected, with onset of the disease at
a young age, and possibly with bilateral
disease.
Life-style factors such as alcohol con-
sumption and lack of physical activity have
been reported to increase breast cancer
risk;
[5]
obesity is associated with a higher
risk in postmenopausal women.
[6]
The most
established risk factors for breast cancer are
related to life-time hormone exposure;
[7]
early menarche, late age at first childbirth
and late menopause.
[8]
All of these are gen-
erally associated with only weak or moder-
ate elevations in risk per patient but have
largely influenced rates globally. Thus, the
particularly large increases in breast cancer
incidence observed recently among His-
panic and Hispanic American women are
attributed to delayed childbearing.
Not only endogenous hormones may
affect breast cancer development but exog-
enous hormones also bestow an increased
risk as studies of women taking the pill and
of postmenopausal women on hormone
replacement therapy have shown; women
currently taking the pill have a 1.24 relative
risk
[9]
and women on hormone replacement
therapy have a 1.3 relative risk when taking
only estrogens and a 2.0 relative risk when
taking estrogens and progesterone.
[10]
All these factors taken together account
only for some of the increase in breast cancer
incidence and the question arises whether
the growing number of breast cancer cases
since the 1940s may also have something to
do with the increase in man-made persistent
chemicals in our environment that has oc-
curred in parallel. Evidence has accumulat-
ed that some of these substances like certain
organochlorine compounds, including agri-
cultural pesticides, such as p,p’-dichlorodi-
phenyltrichloroethane (DDT), chlordane,
lindane, dieldrin, and industrial chemicals
such as polychlorinated biphenyls
[11−13]
are
biologically active and may disrupt the en-
docrine system in multiple different ways
(see other articles in this issue); they can
impair the reproduction of birds, fish and
other animals, affect cognitive function, the
immune system and many other organs in
various animal models. What about their
impact on humans, more specifically the
breast cancer problem?
Breast Cancer and Endocrine
Disruptors
The correlation between the accumula-
tion of persistent chemicals and an increase
in reproductive disorders, such as decreased
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Breast Cancer: The Facts
Breastcancer isacomplexandmultifactorial
disease. It comprises 18 distinct histological
subtypes
[1]
and is clinically extremely het-
erogeneous. As one of the most commonly
diagnosed human tumors it strikes one out
of eight women in Switzerland, and is a
leading cause of cancer death worldwide.
[2]
Age-adjusted incidence has increased by
about 1% per year from 1940 to 1980 and
continues to rise,
[3]
with a growing number
of women below the age of 40 affected by
breast cancer in recent years.
[4]
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sperm counts (see Germond and coworkers
in this issue
[14]
) together with the observa-
tions in wild life have raised the concern
that there may be a causal link between
hormone-dependent cancers and exposure
to endocrine disruptors but proofs are dif-
ficult to come by. A case has been made for
the organochlorine, dieldrin formerly used
as an insecticide. A Danish study demon-
strated that serum levels of dieldrin were
associated with a significantly increased
dose-related risk of breast cancer.
[15]
Epidemiology identified classical car-
cinogens and provided the proof that tar,
tobacco, and asbestos are causal in the gen-
esis of different malignancies such as testic-
ular, lung and bladder cancers.As persistent
chemicals are ubiquitous, epidemiologists
are faced with the problem that there are no
unexposed ‘controls’ that would allow them
to assess the effects of exposure; even peo-
ple in remote locations, such as Canada’s
Baffin Island, harbor traces of PCBs, DDT,
and dioxins.
Given the large number of these com-
pounds in our environment − more than
100 000 chemicals are registered in the EU
− human beings are exposed to a complex
mixture of chemicals, that may interact in
many different ways.
[12,16]
Another problem is the long delay
between exposure and effect. Cancer is
thought to arise from normal cells that
evolve into cancer cells passing through
different stages, reflected in the multistep/
multigene model of carcinogenesis (Fig.
1). In the case of breast cancer the target
cells are the epithelial cells that make up the
milk ducts in the breast. The driving forces
in tumorigenesis are held to be heritable
changes, i.e. mutations, in multiple, inde-
pendent genes. Mutations may occur spon-
taneously or as a result of an environmental
agent and can take decades to accumulate.
Cells may also be altered heritably by epi-
genetic mechanisms, these confer changes
on chromatin and DNA that are stable over
rounds of cell division but do not involve
changes in the underlying DNA sequence.
How epigenetic changes are acquired dur-
ing tumorigenesis is poorly understood and
an area of intense investigation. Of note is
that several endocrine disruptors have been
shown to elicit epigenetic changes.
[17,18]
In the case of breast cancer, hormones
impinge on this evolution at various stages
through as yet poorly understood mecha-
nisms. A subset of the milk duct cells has
receptors for estrogens and progesterone
and serve as antenna that give out signals to
neighboring cells in response to hormonal
stimulation.
[19]
The hormones not only trig-
ger cell proliferation/division but alter the
microenvironment, they change intercel-
lular communication, and have systemic
effects with secondary consequences for
the breast tissue. All these changes are im-
portant for the formation of new milk ducts
during normal breast development and may
promote progression of breast cancer.
Thus, endocrine disruptors like the en-
dogenous hormones may act at any stage of
the disease. On the one hand they may act
along with the hormones but they may also
have hormone-independent epigenetic ef-
fects. As the disease takes years or decades
to become clinically apparent a myriad
of exposures will have occurred making
it impossible to discern which of them is
relevant to the disease. Once diagnosis is
made and levels of chemicals measured, the
information obtained may not be necessar-
ily informative.
Lessons from the DES Story: A New
Dimension to the Cancer Problem
In addition to acting at distinct stages
of tumorigenesis as tumor initiators and/
or tumor promoters, endocrine disruptors
are adding a new dimension to the cancer
problem. This insight was gained from the
diethylstilbestrol (DES) experience. DES is
an orally active synthetic estrogen that was
first synthesized in 1938 and prescribed by
doctors in the United States from 1940 to
1971 to help pregnant women who had had
miscarriages or premature deliveries in the
past. It was given to about 4 million women
during this time. The use of DES declined
in the 1960s after studies had shown that
it might not prevent pregnancy complica-
tions. In 1971, the Food and Drug Admin-
istration advised doctors to stop prescribing
DES during pregnancy when it was estab-
lished that the drug could interfere with the
development of the reproductive system in
a fetus when it was given during the first
five months of a pregnancy.
DES was linked to a rare cancer called
clear cell carcinoma of the vagina and cer-
vix in daughters of women who used DES
during pregnancy.
[20]
This cancer of the
vagina or cervix usually occurs in DES-
exposed daughters in their late teens or in
their early 20s. DES-exposed daughters are
about 40 times more likely to develop this
cancer than women not exposed to DES in
the womb and they also have an increased
risk of developing abnormal, premalignant
cells in the tissue of the cervix and vagina.
These observations were the first indica-
tion that exposure to endocrine-disrupting
substances in utero can confer an increased
cancer risk in humans. What about breast
cancer? Consistent with the previous stud-
ies showing that exogenous hormones af-
fect breast cancer risk as discussed above,
women who were given DES were found
to have an about 30% higher risk of breast
cancer than women who had not been ex-
posed to this drug
[21,22]
increasing the likeli-
hood of getting the disease from 1 in 8 up
to 1 in 6. The question of whether the DES
daughters would show increased breast
cancer incidence has long awaited a re-
sponse as these women needed to reach the
age at which breast cancer normally occurs.
In 2006, a study, which followed more than
5000 women who had been exposed to DES
in utero, found a 1.9 relative risk for breast
cancer after age 40 and 3.0 relative risk for
cancers at over 50 years of age.
[23]
This is
the first evidence in humans that exposure
Fig. 1. Schematic representation of multistep carcinogenesis in the breast: Shown are cross sections
of a milk duct at different stages of the development of a breast carcinoma. Lumenal epithelial cells
(yellow) line the lumen of the milk duct. A layer of elongate myoepithelial cells surrounding the luminal
epithelial cells. Both epithelial cell layers are separated from surrounding connective tissue by the
basal lamina (green). Genetic and epigenetic changes are acquired as a normal cell turns into a tumor
cell. These changes drive alterations in the cell’s behaviour. A carcinoma in situ can remain quiescent
for many years and eventually break through the basal lamina into the surrounding tissue (invasive
carcinoma) and can then seed to distant organ sites (metastasis). Hormones affect the carcinogenic
process at all stages (red arrows). Endocrine disruptors interfere with the hormonal regulation at all
stages and may more directly affect breast carcinogenesis through epigenetic mechanisms (yellow
arrows).
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to endocrine disruptors in utero can affect
breast cancer risk.
A similar link between the uterine en-
vironment and breast cancer risk had been
suggested by the observation that factors
such as twin pregnancies and maternal
preeclampsia, two conditions with in-
creased estrogen levels, confer increased
breast cancer risk on the offspring.
[24,25]
This raises the concern that environmental
exposures, although they are very subtle,
may need to be considered more seriously
because they are so prevalent. Evidence has
accumulated from animal models that low
dose exposure both in utero and in the adult
organism has effects on various organ sys-
tems, among them the breast.
The Case of Bisphenol A
A compound that is structurally close-
ly related to DES is bisphenol A (BPA,
2,2-bis-(4hydroxyphenyl) propane). It was
developed before DES but initially rejected
for medical applications as it was too weak-
ly estrogenic. Later BPA found its way on
a different market and is produced in large
amounts, 2.2 million tonnes world-wide
in 2003.
[26]
BPA is primarily used in the
synthesis of polycarbonate plastic, epoxy
resins and as an additive to other plastics.
Because of its presence in many consumer
goods such as food containers, dental seal-
ants, some flame retardant and water sup-
ply pipes, there is widespread human expo-
sure.
[27,28]
Plasma levels of BPA in pregnant
women show a range between 0.3 and 18.9
ng/ml.
[29]
Environmentally relevant doses have
been administered to different animal mod-
els and a plethora of effects has been re-
vealed. Exposures of animals both as adults
and in utero result in changes in various or-
gan systems such as the brain, the reproduc-
tive system, and the immune system.
[30]
Estrogens bind to two different nuclear
hormone receptors, the estrogen receptor
α (ERα) and its cousin, the estrogen re-
ceptor β (ERβ). In addition to interacting
with the ERα, which is the important form
in the breast
[31]
and in other female repro-
ductive organs,
[32]
BPA actually binds with
higher affinity to its cousin the ERβ, which
is expressed in almost all tissues of the
body. Furthermore BPA binds, albeit with
lower affinity to the androgen receptor
[33,34]
and the thyroid receptor.
[35]
BPA has been
shown to modify both expression and ac-
tivity of cytochrome p450
[36,37]
and can act




detailed review of the mechanisms of action
of BPA the reader is referred to ref. [39]).
BPA perinatal exposure triggers pre-
mature onset of puberty.
[40]
This in itself
could indirectly contribute to an increase
in breast cancer risk as early menarche is a
risk factor. However, the work of Dr. Soto
and colleagues established that perinatal
BPA exposure at environmentally relevant






changes that cannot be explained by the
earlier onset of puberty, pointing to addi-
tional biological activities of BPA with re-
gards to the mammary gland. In rats, which
were exposed to BPA in utero hyperplasias
and dysplasias, tumor precursor lesions,
were detected in the mammary glands of
adult rats.
[43]
Mechanisms of BPA in vivo
In the framework of the NRP50 pro-
grammewesetout to lookat themechanisms
underlying the changes elicited by BPA in
vivo. Because of the myriad of interactions
in endocrine signaling at the organismal
level it is difficult to dissect mechanisms in
in vivo models. As a first step we reduced
biological variation by using inbred rather
than outbred mice used in previous experi-
ments. We chose the C57Bl6 mouse strain
chosen because it is frequently used for ge-
netic manipulations of the mouse germline
allowing us to make use of mouse strains
with specific gene deletions. However,
C57Bl6 mice were known to breed less
well and have dampened responses to es-
trogens compared to outbred mice, raising
the concern that the subtle biological effects
of BPA administration would be difficult to
discern. Concomitantly, we changed the
route of administration from the subcutane-
ously implanted drug releasing pumps used
previously to oral administration to breed-
ing mice via drinking water in order to more
closely mimic the human situation where
exposure is oral. In this way the offspring
was exposed during intrauterine develop-
ment and during the first three weeks of life
through the mothers’ milk. Upon weaning
the pups were housed in cages with BPA-
free drinking water.
As observed previously, the develop-
ment of the milk ducts in pubertal mice
showed a biphasic response to low dose
BPA with maximal effect at 2.5 µg/kg
bodyweight/day; the range tested extended
from 25 ng/kg bodyweight/day to 250 µg/
kg bodyweight /day (Mallepell et al., un-
published observations). Changes in the
layout of the ductal tree in adult females
were not detected. However, counts of the
cells making up the milk ducts, a more sen-
sitive approach to reveal increased prolif-
eration than the morphological evaluation,
revealed that the epithelial cell numbers
were consistently increased about 1.5 fold
(Mallepell et al., unpublished observations,
Fig. 2) in adult mice. This observation is
of concern as an increase in epithelial cell
number reflects an increase in the number
of cells that can potentially undergo malig-
nant changes. At the population level even
a minor increase in risk can have large con-
sequences when a disease is very prevalent
such as breast cancer.
To address whether BPA exposure
changes the endocrine milieu or the breast
epithelium itself, we grafted epithelial cells
from exposed mice into untreated mice.
The grafted epithelium retained features
age [months]
Fig. 2. Perinatal BPA exposure increases cell numbers in the mammary gland: Graph representing
cell counts taken in six independent experiments. Age of mice (either 2 or 3 per group) in months
is plotted on the x axis, the relative cell counts are plotted on the y-axis. Open bars represent mice
that were not exposed to BPA closed bars represent mice whose parents drank water with 25 µg
of BPA/liter, the calculated exposure is 2.5 µg/kg bodyweight per day. Note that mammary glands
from exposed mice show consistently higher cell counts that the mammary glands from unexposed
controls.
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that had been induced by the exposure in
utero when it was growing in an unexposed
host. This indicates that permanent changes
in the epithelium have occurred that persist
in a normal endocrine milieu (Mallepell
et al., unpublished observations), whether
these changes were elicited by direct action
of BPA on the mammary epithelium or are
indirect effects of BPA acting on the mam-
mary stroma or in other organs remains to
be addressed. In any case, the identification
of these persistent changes in a specific cell
type opens the possibility to perform fur-
ther analyses to identify specific biochemi-
cal changes.
Investigations are ongoing with mice
lacking either one or both copies of the
ERα and/or the ERβ gene to assess to what
extent the two proteins are involved in me-
diating the changes elicited by BPA.
Perspectives
Although research indicates that man-
made chemicals may be causing problems
in wildlife, at least in localized areas, it
is still difficult to determine which hor-
mone mimics pose what health risks for
people. The studies on DES patients and
their offspring indicate that humans are
also susceptible to endocrine disruptors at
different developmental stages. Evidence
from animal model with environmentally
relevant doses of BPA establishes a role
of endocrine disruption in breast and in
prostate cancer (not discussed here). The
studies illustrate the complexity of the
mechanisms of action and its biological
effects. BPA however is only one of a
myriad of factors that we are exposed to.
So should we ignore warning signs or is
it time to take the issue into consideration
in order to elaborate a preventive public
health policy?
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